- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
Shanghai, March 25, 2016 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulated its partners Ambrx and Zhejiang Medicine Company (ZMC) for completing dose of the first patient for ARX788, a novel antibody-drug conjugate (ADC) product candidate for treating breast cancer and gastric cancer in Australia.
ARX788 was developed by Ambrx based on its innovative EuCodeTM technology platform. In June 2013, Ambrx and ZMC formed an innovative collaboration to develop ARX788 in China with world-class standards.
As part of the collaboration, WuXi Biologics provided comprehensive, integrated services for ARX788 from clones to IND. WuXi Biologics successfully scaled up manufacturing processes for the novel toxin/linker, the monoclonal antibody, the ADC drug substance and drug product under cGMP condition. These activities were all conducted at WuXi Biologics’ facilities within 100 miles, eliminating the complex transportation issues often associated with ADCs. This project represents the first site-specific ADC using a non-natural amino acid technology. It also represents the first reported case of large-scale manufacture of such an ADC for clinical applications.
IND for ARX-788 was approved in Australia and New Zealand. The IND application was also accepted by Chinese CFDA last month (The CFDA has been renamed NMPA).
“We congratulate our partner for achieving this critical milestone of dosing the first patient. We are very pleased to have completed this complicated ADC project within only 20 months, which manifested our strong value proposition of the integrated solution provider,” said Dr. Chris Chen, CEO of WuXi Biologics.
“We are very excited about this key achievement for our site-specific antibody drug conjugate programs. This demonstrates that our EuCodeTM technology platform is ready for commercial product development,” said Dr. Alex Qiao, CEO of Ambrx. “We are also very happy about this collaboration. WuXi Biologics’ integrated service enables Ambrx’s innovative business model to bring our novel drug to patients with great efficiency.”
“This project represents one of the first case studies of using the same CMC and preclinical package for global simultaneous filing,” said Dr. Ge Li, Chairman of WuXi Biologics. “This collaboration showcases WuXi Biologics’ integrated, open-access R&D services platform and enables our partners to develop innovative products efficiently and cost-effectively to benefit patients around the world.”